Shanghai BDgene Co., Ltd. is advancing a novel CRISPR/Cas9 gene editing therapy (BD114) for the treatment of HPV-16-related high-grade squamous intraepithelial lesions (HSIL). The study is currently recruiting participants in Shanghai, China, with an estimated completion date in December 2026. The market for cervical cancer prevention and treatment is significant, particularly in regions with high HPV prevalence. If successful, BD114 could position BDgene as a leader in gene therapy for HPV-related conditions, although it will face competition from existing treatments and emerging therapies. Diligence should focus on regulatory pathways, potential market entry barriers, and the evolving landscape of gene editing technologies.